Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are cancers of the blood and bone marrow.
In AML, the bone marrow makes too many myeloblasts, red blood cells, and platelets. Myeloblasts are a type of white blood cell.
In ALL, the bone marrow makes too many lymphocytes, which are another type of white blood cell.
This article outlines the difference between AML and ALL, as well as their associated risk factors and symptoms. It also provides information about diagnosis, treatment, and survival rates.
AML and ALL are both cancers of the blood and bone marrow.
The main difference between the two is that AML affects the production of myeloblasts, red blood cells, and platelets, whereas ALL mainly affects the production of lymphocytes.
Myeloblasts are a type of precursor white blood cell that mature into either neutrophils, basophils, or eosinophils. These types of white blood cell engulf and dissolve different pathogens, such as bacteria and viruses.
Lymphocytes are another type of white blood cell. There are two main types: B lymphocytes and T lymphocytes.
B lymphocytes produce antibodies, whereas T lymphocytes help kill tumor cells and regulate the immune response.
Certain factors can increase a persons risk of developing either AML or ALL. Below, we outline some of the risk factors experts associate with each of these conditions.
AML risk factors include:
ALL is more common in the following groups of people:
Other risk factors for ALL include:
Both ALL and AML are very serious conditions that develop rapidly.
According to a 2021 review, AML is the most common type of leukemia among adults, accounting for around 80% of all cases.
Authors of the review observe that age plays an important role in survival rates for AML. Following treatment, around 15% of people above the age of 60 years will recover, compared with 40% of people below the age of 60 years.
According to another 2021 review, ALL is most common among children aged 210 years. People who are younger than 30 years of age are more likely to experience successful treatment than those who are older. Also, around 30% of adults with ALL fully recover.
AML and ALL are both acute types of leukemia, and their symptoms are similar.
Generally, symptoms of AML and ALL include:
Many of these symptoms overlap with other, less serious conditions. However, anyone who is concerned about symptoms should consult a doctor, especially if they are experiencing a cluster of symptoms.
Symptoms of AML and ALL are similar, and therefore doctors need to perform several tests and physical exams before reaching a diagnosis.
To diagnose AML, a doctor will first request a blood smear test to check for abnormalities in the red and white blood cells, and platelets. They may then request a bone marrow biopsy to check for abnormal cells in the bone marrow.
If these tests indicate AML, the doctor may then order cytometry and cytogenetic tests to determine the type of AML a person has.
Cytometry assesses characteristics of cells, such as:
Cytogenetic tests assess changes to chromosomes within a sample. This may include:
If a person is presenting with symptoms of ALL, a doctor will request a complete blood count to check the numbers of different blood cells in the blood. They will also measure levels of electrolytes and urea in the blood.
A doctor may also request imaging scans of the abdomen and pelvis to help determine the stage of the cancer.
In some cases, a doctor may be concerned that the cancer has spread to the central nervous system. A person may then receive a lumbar puncture to check for the presence of lymphoblasts in their spinal fluid.
Treatment options for AML and ALL are similar.
In both instances, a person will usually receive induction therapy. This is the first-line treatment that aims to put the disease into remission. It typically consists of chemotherapy.
If a person goes into remission after induction therapy, they will begin consolidation therapy. This is the next stage of treatment that kills off any remaining cancer cells in the body in order to help maintain disease remission.
Consolidation therapy for AML may consist of high-dose chemotherapy, hematopoietic cell transplantation (HCT), or both.
HCT involves transplanting the abnormal blood-forming stem cells with healthy blood-forming stem cells from the persons own body or from a donor.
Consolidation therapy for ALL typically consists of multidrug chemotherapy.
In some cases, a doctor may recommend stem cell therapy (SCT). Like HCT, SCT involves replacing the abnormal blood-forming stem cells with healthy ones either from the persons own body or from a donor.
Due to improvements in chemotherapy treatment, SCT for ALL is becoming less common.
People with leukemia may also receive other types of treatment, such as:
The types of additional treatment a person receives will depend on several factors, including:
Below, we outline the relative survival rates for AML and ALL.
A relative survival rate helps give an idea of how long a person with a particular condition will live after receiving a diagnosis compared with those without the condition.
For example, if the 5-year relative survival rate is 70%, it means that a person with the condition is 70% as likely to live for 5 years as someone without the condition.
It is important to remember that these figures are estimates. A person can consult a healthcare professional about how their condition is going to affect them.
According to the National Cancer Institute (NCI), between the years 2011 and 2017, the 5-year relative survival rate for AML in the United States was 29.5%.
This means that 29.5% of people in the U.S. who received an AML diagnosis went on to live 5 years or longer following their initial diagnosis.
Between 2016 and 2018, the lifetime risk of developing AML was 0.5%. The NCI estimates that, during the same time frame, 66,988 people were living with the condition.
The 5-year relative survival rate for ALL is 69.9%.
Between 2016 and 2018, the lifetime risk of developing ALL was 0.1%. According to the NCI estimates, during the same time frame, 103,536 people were living with ALL.
A person who has recently received a diagnosis of AML or ALL may want to find out more about their condition and its treatment.
Below are some questions individuals may want to ask a doctor or wider medical team:
Both AML and ALL are acute types of leukemia. AML causes the body to produce too many myeloblasts, platelets, and red blood cells. By contrast, ALL increases the production of lymphocytes.
Also, both AML and ALL are acute leukemias, and therefore both have similar symptoms. These may include flu-like symptoms, weakness, and fatigue.
Typically, the first-line treatment for both AML and ALL is chemotherapy, which aims to put the disease into remission. Follow-up consolidation therapy can help destroy any remaining cancer cells and maintain remission.
A person can ask a doctor for specific information on the type of leukemia they have and the treatment options available to them.
- COVID-19: Researchers warn against overhyping early-stage therapies - Medical News Today - October 26th, 2021
- OpRegen Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D. - Yahoo Finance - October 26th, 2021
- Insights & Outcomes: Place cells, planarians, and 'prewet' proteins - Yale News - October 26th, 2021
- IMAC Holdings The Back Space Announces the Completion of Two Additional Retail Spinal Care Locations - Yahoo Finance - October 26th, 2021
- JEFFERSON PARISH PARTNERS WITH LOUISIANA DEPARTMENT OF HEALTH TO ADMINISTER FREE FLU SHOTS AND COVID-19 VACCINES ON NOVEMBER 6, 2021 - 10-25-YYYY -... - October 26th, 2021
- Male Infertility Could Be Treated With Monkey Cells; New Study Shows How These Animals Could Help Address the Condition - Science Times - October 26th, 2021
- Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients - Yahoo... - October 26th, 2021
- New findings may help widen therapeutic interventions for B-cell acute lymphoblastic leukemia - News-Medical.Net - October 25th, 2021
- Getting to Know Kate Roth at Beacon Integrative Medical Center in Rexburg - East Idaho News - October 25th, 2021
- Global Cell Therapy Market Report 2021-2028 - Growing Adoption of Regenerative Medicine & Introduction of Novel Platforms and Technologies -... - October 25th, 2021
- Vertex reports positive results for first patient in Type 1 diabetes trial - BetaBoston - October 23rd, 2021
- Morris receives grant for stem cell research - The Source - Washington University Record - October 23rd, 2021
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes - PMLiVE - October 23rd, 2021
- McLaughlin Research Institute receives $5 million gift to support neurology studies - Great Falls Tribune - October 23rd, 2021
- AML medication and treatment: What to know - Medical News Today - October 23rd, 2021
- U S Stem Cell : USRM to Focus on Animal Health and Lead Pet-Care Innovation - Marketscreener.com - October 19th, 2021
- Opinion: Why Colin Powell's death should not be framed as the death of a vaccinated person - Poynter - October 19th, 2021
- Quris combines AI with patient on a chip to speed drug development and reduce animal testing - TechCrunch - October 19th, 2021
- Dr. Helen Heslop elected to the National Academy of Medicine - Baylor College of Medicine News - October 19th, 2021
- Researchers report long-lasting effects of gene therapy in children with deadly immune disorder - News-Medical.Net - October 19th, 2021
- Coronavirus: How does misinformation spread, and how can we stop it? - The Jerusalem Post - October 17th, 2021
- Dr. Kahl on the Potential Utility of Frontline CAR T-Cell Therapy in MCL - OncLive - October 17th, 2021
- FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer - Business Wire - October 17th, 2021
- Global Stem Cell and Primary Cell Culture Medium Market 2021 Trends and Leading Players Analysis 2027 Merck, STEMCELL Technologies, Irvinesci, Cell... - October 15th, 2021
- Dr. Erba on the Evolution of Treatment in MCL - OncLive - October 15th, 2021
- After no stem cell donors stepped up to saved her son, mom continues to help others facing the same challenge - Chicago Tribune - October 15th, 2021
- International ZIM Network: SmartMed - Regenerative Solutions for the Therapies of Tomorrow - Business Wire - October 15th, 2021
- Are 'robot massages' the future of muscle repair? - Medical News Today - October 15th, 2021
- What the FDA Panel's Moderna Booster Shot Vote Means and What's Next - NBC Chicago - October 15th, 2021
- Phase 2 Clinical Trial Data of NurOwn in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in... - October 15th, 2021
- R3 Stem Cell & Exosome Therapy: Joint & Back Pain, Avoid ... - October 13th, 2021
- Stem Cell PhD Program | Institute for Stem Cell Biology ... - October 13th, 2021
- New stem cell identified by Sanford Burnham Prebys researchers offers hope to people with rare liver disease - Newswise - October 13th, 2021
- Repurposed Drug Reverses Signs of Alzheimers in Mice, Human Cells - The Scientist - October 13th, 2021
- Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development - StreetInsider.com - October 13th, 2021
- What the latest COVID research says about breakthrough cases and transmission : Shots - Health News - NPR - October 13th, 2021
- HNF collaborates with Rarebase on a Drug Discovery Platform to develop treatments for Charcot-Marie-Tooth (CMT) - PRNewswire - October 13th, 2021
- Autologous HSCT Continues to Show Sustained Benefit in MCL, But Targeted Therapies May Challenge its Role as Standard Frontline Treatment -... - October 13th, 2021
- Bartolo Coln, Winner Of The Cy Young, Wins Lawsuit In Case Of Stem Cell Treatment To Which He Was Subjected Before His Return To The Major Leagues. -... - October 11th, 2021
- The Impact Of Market Restrictions On The US Stem Cell Biomaterials Market - Med Device Online - October 11th, 2021
- Vitro Biopharma Inc. July 31st 2021; 3rd Quarter ended Financial Results of Operations and Shareholder Letter. - Yahoo Finance - October 11th, 2021
- Top US Leukemia Experts from Academia, Industry and Public Sector Coming Together at Acute Myeloid Leukemia Conference on October 22 - OncLive - October 11th, 2021
- Precision medicine data dive shows water pill may be viable to test as Alzheimer's treatment - National Institutes of Health - October 11th, 2021
- Treating Early Relapse in Follicular Lymphoma - Targeted Oncology - October 11th, 2021
- Humans and Chimpanzees Use a Part of Their DNA in Different Ways - Technology Networks - October 11th, 2021
- A stem cell treatment for MS offers some patients hope. But is it hope that will last? - WHYY - October 9th, 2021
- CAR T Offer New Treatment Option for Non-Hodgkin Lymphoma - Targeted Oncology - October 9th, 2021
- FDA Advisory Committee Recommends Maribavir to Treat Cytomegalovirus CMV Infection and Disease - Contagionlive.com - October 9th, 2021
- What surgeons are saying about regenerative medicine in 2021 - Becker's Orthopedic & Spine - October 9th, 2021
- Study illuminates how BRD4 protein directs the spatial organization of DNA within cell nucleus - News-Medical.net - October 9th, 2021
- Cellular Therapy Strategies Offer the Prospect of Deep Remissions for Multiple Myeloma - OncLive - October 9th, 2021
- Anti-CD47 Therapy and Other New Approaches to the Treatment of Myelodysplastic - Targeted Oncology - October 9th, 2021
- ViaCyte to Present at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa - PRNewswire - October 7th, 2021
- Seattle Stem Cell Therapy Clinic - Seattle Sports Medicine ... - October 7th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - PRNewswire - October 7th, 2021
- New Stem Cell Approach Through Using Wavelength Laser Might have Discovered Why Humans Lose Hair - Tech Times - October 5th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - WMTV - NBC15 - October 5th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- Northwesterns SPORE has made advances in understanding the genetic basis of glioblastoma - News-Medical.Net - October 5th, 2021
- NextCure Announces New Appointments to its Board of Directors - GlobeNewswire - October 5th, 2021
- Therapy and Prevention Strategies for Myocardial Infarction | IJN - Dove Medical Press - October 3rd, 2021
- Lack of awareness about blood stem cell donation is one of the leading causes for low number of donors in In.. - ETHealthworld.com - October 3rd, 2021
- Advanced technique offers new insights about the dynamics of gliomas - News-Medical.net - October 3rd, 2021
- "Stem cell-based therapeutics poised to become mainstream option - BSA bureau - October 2nd, 2021
- The stem cell revolution isnt what you think it is - New Scientist News - October 2nd, 2021
- Stem cell agency gives out $2 million a minute - Capitol Weekly - October 2nd, 2021
- Researching the Safety and Effectiveness of Stem Cells to Treat 'Long Covid' - Entrepreneur - October 2nd, 2021
- United States Regenerative Medicine Markets to 2026: Focus on Cell Therapies, Gene Therapies, Progenitor & Stem Cell Therapies, Tissue Engineered... - October 2nd, 2021
- U.S. FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Business... - October 2nd, 2021
- Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA - Business Wire - October 2nd, 2021
- Stem Cell Umbilical Cord Blood Market in North America 2021 Sees Growth Due to Rising Spending Capacity and Suitable Payment Plans - PRNewswire - October 2nd, 2021
- BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS - BioSpace - October 2nd, 2021
- Macomics Announces New Hires that Expands its Macrophage-based Drug Discovery R&D Team - BioSpace - October 2nd, 2021
- Stanford neuroscientist's 'assembloids' pave the way for innovative brain research - Scope - October 2nd, 2021
- At the crossroads of reproductive and regenerative medicine: new opportunities for preserving and restoring fertility - ESHRE - September 25th, 2021
- Doctors Debate: Do CAR T Cells and Transplantation Both Have a Place in Aggressive B-Cell Lymphoma Treatment? - Targeted Oncology - September 25th, 2021
- Global Stem Cell Alopecia Treatment Market 2021 Development Status,Industry Insights and Forecast Research Report 2027 Stillwater Current -... - September 25th, 2021
- New gene therapies may soon treat dozens of rare diseases - American Society for Biochemistry and Molecular Biology - September 25th, 2021
- BioRestorative Therapies Receives Notice of Allowance for Patent Application in Israel for its Metabolic Program - GlobeNewswire - September 25th, 2021
- Shifts Away From R-CHOP Treatment Shows Improved EFS and OS Benefit in MCL - Targeted Oncology - September 25th, 2021